यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

pfizer europe ma eeig - tafamidis - amyloidosis - drogi oħra tas-sistema nervuża - vyndaqel huwa indikat għat-trattament ta 'transthyretin amyloidosis f'pazjenti adulti bi polyneuropathy sintomatika stadju-1 biex jittardja l-indeboliment newroloġiku periferali.

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

merck sharp & dohme b.v. - doravirine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with hiv 1 without past or present evidence of resistance to the nnrti class.

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. l-użu ta ' dan il-vaċċin għandha tkun skond ir-rakkomandazzjonijiet uffiċjali.

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

vétoquinol sa - emodepside, praziquantel, tigolaner - anthelmintics, - qtates - for cats with, or at risk from, mixed parasitic infestations. the veterinary medicinal product is exclusively indicated when ectoparasites, cestodes and nematodes are targeted at the same time.

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

gilead sciences ireland uc - bictegravir, emtricitabine, tenofovir alafenamide, fumarate - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - biktarvy is indicated for the treatment of human immunodeficiency virus 1 (hiv 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir. (ara sezzjoni 5.

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

eli lilly nederland b.v. - selpercatinib - carcinoma, non-small-cell lung; thyroid neoplasms - aġenti antineoplastiċi - retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced ret-mutant medullary thyroid cancer (mtc)advanced ret fusion-positive non-small cell lung cancer (nsclc) not previously treated with a ret inhibitoradvanced ret fusion-positive thyroid cancer who require systematic therapy following prior treatment.

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

gilead sciences ireland uc - emtricitabine, tenofovir alafenamide - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (hiv-1).

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - epatite Ċ, kronika - antivirali għal użu sistemiku - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 u 5.

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

viiv healthcare bv - lamivudine - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - epivir huwa indikat bħala parti mit-terapija kombinata antiretrovirali għat-trattament ta 'adulti u tfal infettati bil-virus ta' l-immunodefiċjenza umana (hiv).

यूरोपीय संघ - माल्टीज़ - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - epatite Ċ, kronika - antivirali għal użu sistemiku - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 u 5. għall-vajrus tal-epatite Ċ (hcv) ġenotip-attività speċifika ara sezzjonijiet 4. 4 u 5.